《港股》恆指半日跌232點 小米回吐逾4% 個別藥股見追捧
市場觀望美國上月新增非農數據及《大而美法案》,港股早市在個別股份受壓下走軟。恆指高開12點,初段升47點見24,269點後回落,曾跌301點一度低見23,920點,半日跌232點或1%,報23,989點;國指跌108點或1.2%,報8,616點;恆生科技指數跌63點或1.2%,報5,205點。大市半日成交總額1,305.84億元。
小米(01810.HK)指小米汽車先解決國內交付問題,2027年纔會考慮出口,小米回吐4.4%報57.5元。小鵬(09868.HK)上月交付3.46萬輛增2.24倍,股價升1%。零跑(09863.HK)及長汽(02333.HK)升3.5%及2.1%,比亞迪(01211.HK)升0.7%報123.1元。電池股寧德時代(03750.HK)升1.9%,鋰業股贛鋒鋰業(01772.HK)升5.9%。
科技股方面,南非Naspers唱淡美團(03690.HK)國際擴張,直言缺乏信心考慮減持股份,美團跌2.5%。阿里(09988.HK)跌3.6%報105.5元。騰訊(00700.HK)及中芯(00981.HK)跌0.5%及0.2%,快手(01024.HK)、京東(09618.HK)及嗶哩嗶哩(09626.HK)跌1.4%至1.8%,此外,心動(02400.HK)、阿里健康(00241.HK)及新東方(09901.HK)跌3.4%至3.8%,金軟(03888.HK)跌7.6%,萬國數據(09698.HK)升6.4%。
康方生物(09926.HK)研發首個雙抗ADC藥物治療晚期實體瘤的Ia期臨牀研究完成首例受試者入組,該股升11.3%。信達生物(01801.HK)獲花旗及中金上調目標價,股價升6.5%。其他醫藥股方面,榮昌生物(09995.HK)升5.1%,百濟神州(06160.HK)及諾誠健華(09969.HK)升逾3%,中生製藥(01177.HK)升2.6%。
金融股方面,匯控(00005.HK)及港交所(00388.HK)跌0.3%及1.3%,友邦(01299.HK)升0.6%,內銀股農行(01288.HK)及招行(03968.HK)跌1.7%及2.5%,內險股人保(01339.HK)及衆安在線(06060.HK)各跌2.7%。本港5月零售銷售勝預期,獲大摩上調投資評級至「增持」的九倉置業(01997.HK)升7.3%,希慎(00014.HK)升2.3%。發展商新世界(00017.HK)股價吐6.6%。
消費股方面,泡泡瑪特(09992.HK)跌3.4%,蜜雪(02097.HK)及毛戈平(01318.HK)跌3.8%,老鋪黃金(06181.HK)跌1.6%。此外,週六福(06168.HK)及奈雪(02150.HK)跌11.7%及10.7%。
其他股份方面,多點數智(02586.HK)擬申請香港穩定幣牌照,股價升32.7%報11.96元,成交逾11億元。鋼鐵股昨日炒高後今日回落,鞍鋼(00347.HK)及馬鋼(00323.HK)跌3.8%及5.9%,重鋼(01053.HK)跌14%報1.48元,成交12.7億元,美國與越南達成關稅協議,申洲(02313.HK)及裕元(00551.HK)升2.3%及1.7%,創科(00669.HK)跌近1%。丘鈦(01478.HK)升3.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.